Helus Pharma Completes Phase 3 HLP003 Enrollment in MDD
NEW YORK and TORONTO, Aug. 14, 2026 Helus Pharma is advancing its late-stage clinical development strategy for novel serotonergic...
Major Depressive Disorder
Advertisement
Mapi Pharma Advances Once-Monthly Cariprazine Depot After Positive Phase I/IIa Results
NESS ZIONA, Israel, August 12, 2026 Mapi Pharma Ltd. announced initial clinical results from its ongoing Phase I/IIa study...
Definium Therapeutics Advances DT120 ODT After Positive Phase 3 Results
NEW YORK, August 6, 2026 Definium Therapeutics reported its second quarter 2026 financial results and recent business highlights, led...
Contineum Therapeutics Affirms Phase 2 Milestones and Cash Runway
SAN DIEGO, July 30, 2026 Contineum Therapeutics, Inc. reported its second-quarter 2026 financial results while reaffirming key clinical development...
LB Pharmaceuticals Accelerates Phase 3 LB-102 Schizophrenia Timeline
New York, July 22, 2026 LB Pharmaceuticals announced that it now expects to report topline results from the pivotal...
Advertisements
AtaiBeckley Completes Patient Dosing in Phase 2b VLS-01 TRD Trial
NEW YORK, July 6, 2026 AtaiBeckley Inc. announced that the final patient has been dosed in Elumina, its international...
NRx Pharmaceuticals Highlights Real-World Ketamine Depression Data
MIAMI, June 5, 2026 NRx Pharmaceuticals, Inc. announced that new real-world evidence presented at the 2026 American Society of...
Definium Therapeutics Begins Phase 3 DT120-ODT Study
WALTHAM, Mass., May 12, 2026 Definium Therapeutics announced that the first patient has been dosed in the pivotal ASCEND...
Johnson & Johnson Showcases Neuropsychiatry Data at APA 2026
TITUSVILLE, N.J., May 11, 2026 Johnson & Johnson announced the presentation of 18 new and encore abstracts highlighting the...
Johnson & Johnson Highlights CAPLYTA Superiority in MDD Study
TITUSVILLE, NEW JERSEY, May 04, 2026 Johnson & Johnson has announced new findings demonstrating that CAPLYTA® (lumateperone) achieved the...
Advertisement
